Evidence map›Paper›PMID 30364933›Full record

ArticleCarcinogenesis2019

Gene expression profiling informs HPV cervical histopathology but not recurrence/relapse after LEEP in ART-suppressed HIV+HPV+ women.

Emmanouil Papasavvas, Andrew V Kossenkov, Livio Azzoni, Nicola M Zetola, Agnieszka Mackiewicz, Brian N Ross, Matthew Fair, Surya Vadrevu, Doreen Ramogola-Masire, Ian Sanne and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Carcinogenesis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Emmanouil PapasavvasThe Wistar Institute, HIV-1 Immunopathogenesis Laboratory, Philadelphia, PA, USA.
Andrew V KossenkovThe Wistar Institute, HIV-1 Immunopathogenesis Laboratory, Philadelphia, PA, USA.
Livio AzzoniThe Wistar Institute, HIV-1 Immunopathogenesis Laboratory, Philadelphia, PA, USA.
Nicola M ZetolaThe Botswana-UPenn Partnership, Department of Radiation Oncology, Gaborone, Botswana.
Agnieszka MackiewiczThe Wistar Institute, HIV-1 Immunopathogenesis Laboratory, Philadelphia, PA, USA.
Brian N RossThe Wistar Institute, HIV-1 Immunopathogenesis Laboratory, Philadelphia, PA, USA.
Matthew FairThe Wistar Institute, HIV-1 Immunopathogenesis Laboratory, Philadelphia, PA, USA.
Surya VadrevuThe Wistar Institute, HIV-1 Immunopathogenesis Laboratory, Philadelphia, PA, USA.
Doreen Ramogola-MasireThe Botswana-UPenn Partnership, Department of Radiation Oncology, Gaborone, Botswana.
Ian SanneClinical HIV Research Unit, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Cynthia FirnhaberClinical HIV Research Unit, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Luis J MontanerThe Wistar Institute, HIV-1 Immunopathogenesis Laboratory, Philadelphia, PA, USA.
The Wistar Institute · USUniversity of the Witwatersrand · ZAUniversity of Pennsylvania · US

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
Shared Resources CoreU54CA190158 · NCI · UNIVERSITY OF PENNSYLVANIA · PI ROBERTSON, ERLE S. · 2014 to 2023
$4.2M
HIV Therapy &Interruption RCT in Resource Poor ClinicU01AI051986 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J · 2005 to 2010
$3.0M
Integrative Approach to Comprehensive Analysis of High Throughput Data on a Cancer Center LevelR50CA211199 · NCI · WISTAR INSTITUTE · PI Andrew V Kossenkov · 2016 to 2026
$1.6M
NCI NIH HHS P30 CA010815NCI NIH HHS R50 CA211199NCI NIH HHS U54 CA190158NIAID NIH HHS U01 AI051986
6 · The paper itself

Abstract

Identification of factors associated with human papillomavirus (HPV) cervical histopathology or recurrence/relapse following loop electrosurgical excision procedure (LEEP) would allow for better management of the disease. We investigated whether gene signatures could (i) associate with HPV cervical histopathology and (ii) identify women with post-LEEP disease recurrence/relapse. Gene array analysis was performed on paraffin-embedded cervical tissue-isolated RNA from two cross-sectional cohorts of antiretroviral therapy (ART)-suppressed HIV+HPV+ coinfected women: (i) 55 women in South Africa recruited into three groups: high risk (HR) (-) (n = 16) and HR (+) (n = 15) HPV without cervical histopathology and HR (+) HPV with cervical intraepithelial neoplasia (CIN) grade 1/2/3 (n = 24), (ii) 28 women in Botswana with CIN2/3 treated with LEEP 12-month prior to recruitment and presenting with (n = 13) and without (n = 15) lesion recurrence/relapse (tissue was analyzed at first LEEP). Three distinct gene expression signatures identified were able to segregate: (i) HR+ HPV and CIN1/2/3, (ii) HR HPV-free and cervical histopathology-free and (iii) HR+ HPV and cervical histopathology-free. Immune activation and neoplasia-associated genes (n = 272 genes; e.g. IL-1A, IL-8, TCAM1, POU4F1, MCM2, SMC1B, CXCL6, MMP12) were a feature of cancer precursor dysplasia within HR HPV infection. No difference in LEEP tissue gene expression was detected between women with or without recurrence/relapse. In conclusion, distinctive gene signatures were associated with presence of cervical histopathology in tissues from ART-suppressed HIV+/HPV+ coinfected women. Lack of detection of LEEP tissue gene signature able to segregate subsequent post-LEEP disease recurrence/relapse indicates additional factors independent of local gene expression as determinants of recurrence/relapse.

Indexed as

AdultAnti-Retroviral AgentsCervix UteriCross-Sectional StudiesFemaleGene ExpressionGene Expression ProfilingHIV InfectionsHumansNeoplasm Recurrence, LocalPapillomaviridaePapillomavirus InfectionsUterine Cervical DysplasiaUterine Cervical NeoplasmsAnti-Retroviral Agents

Identifiers

PMID30364933
PMCPMC6487677
OpenAlexW2898184934

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.